Given the tissue-specific nature of these receptor activation effects, precise targeting of glucagon-family receptors is necessary to provide sufficient treatment for metabolic disease, while also limiting any adverse effects
In general, GLP-1 semaglutide injections may be appropriate for individuals who: Have a Body Mass Index (BMI) of 23 or above based on Asian risk criteria Have excess body weight associated with metabolic risk factors Have experienced difficulty achieving sustained weight reduction through diet and exercise alone Are medically suitable following clinical evaluation In certain cases, individuals with a BMI slightly below the threshold may be considered if they have weight-related metabolic risk factors or other clinical indications
The primary differences between these two models lie in their scope , delivery methods , and operational strategies
Unlike Ozempic, Mounjaro, and Innovent Biologics' efsubaglutide alfa, ecnoglutide won't be covered under China's state-run health insurance scheme for type 2 diabetes
This approach aligns with standard practice in retrospective real-world investigations